CStone Pharmaceuticals

CStone Pharmaceuticals (HKEX: 2616) is a Chinese biopharmaceutical company focused on the development and commercialization of innovative oncology and precision medicines. Founded in late 2015 and headquartered in Shanghai, the company builds its portfolio around immuno-oncology assets and precision oncology therapies targeting cancers with high unmet medical need in China and globally.

The company has launched four innovative medicines and secured 21 new drug application approvals covering nine indications. Its marketed products include sugemalimab (CEJEMLY), an anti-PD-L1 antibody approved for non-small cell lung cancer indications, including marketing authorizations in the European Union and the United Kingdom; pralsetinib (GAVRETO), a RET inhibitor; and avapritinib (AYVAKIT), a KIT/PDGFRA inhibitor for gastrointestinal stromal tumors, with China National Reimbursement Drug List inclusions supporting patient access.

CStone's Pipeline 2.0 advances more than nine candidates spanning multispecific antibodies and antibody-drug conjugates, led by CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody in Phase I/II clinical development, and CS5001, an anti-ROR1 antibody-drug conjugate. The company operates an in-house ADC technology platform and a Translational Medicine Research Center in Suzhou. Revenue comes from product sales, licensing and partnership income, with commercialization partnerships extending sugemalimab's reach to more than 60 countries across Europe, the Middle East, North Africa and Latin America.

Keywords: CStone Pharmaceuticals, biopharmaceutical, China, oncology, immuno-oncology, precision medicine, sugemalimab, CEJEMLY, pralsetinib, GAVRETO, avapritinib, AYVAKIT, antibody-drug conjugate, bispecific antibody, multispecific antibody, non-small cell lung cancer, RET inhibitor, KIT/PDGFRA inhibitor, clinical trials, HKEX 2616, Shanghai